Steven Maestrello, MD
Rheumatology · Richmond, VANPI 1154328938
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 475 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,958, 2.3 times the $854 reported in 2019.
Across 475 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AbbVie$1K
- Pfizer$734
- Novartis$609
- Johnson & Johnson$607
- Lilly USA, LLC$595
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,35498%
- Education$1942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 82 | $1,460 |
| AbbVie | 86 | $1,079 |
| Pfizer | 55 | $734 |
| Novartis | 26 | $609 |
| Johnson & Johnson | 48 | $607 |
| Lilly USA, LLC | 24 | $595 |
| UCB, Inc. | 16 | $382 |
| E.r. Squibb & Sons, L.L.C. | 15 | $299 |
| Genentech USA, Inc. | 12 | $296 |
| Mallinckrodt Hospital Products Inc. | 10 | $296 |
| AstraZeneca | 13 | $292 |
| GSK | 14 | $250 |
| Radius Health, Inc. | 8 | $230 |
| ANI Pharmaceuticals, Inc. | 7 | $171 |
| Boehringer Ingelheim | 5 | $140 |
| Aurinia Pharma U.S., Inc. | 7 | $136 |
| Sandoz | 6 | $135 |
| Fresenius Kabi USA, LLC | 6 | $108 |
| Sanofi | 4 | $100 |
| Organon | 8 | $95 |
| Fidia Pharma USA Inc. | 3 | $66 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $65 |
| Tersera Therapeutics LLC | 2 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| Boston Scientific | 1 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Sobi, Inc | 1 | $28 |
| Mylan Institutional Inc. | 1 | $25 |
| Tonix Medicines, Inc. | 1 | $25 |
| Celltrion USA Inc. | 1 | $25 |
| Pacira Pharmaceuticals Incorporated | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Bristol Myers Squibb | 1 | $17 |
| Bioventus LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TALTZ$113
How this compares
$8,548 in reported general payments places this provider in the 70th percentile of 159 rheumatology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xeljanz XrTofacitinib Citrate | 59 | $400,207 |
| Humira(Cf) PenAdalimumab | 17 | $182,117 |
| Taltz AutoinjectorIxekizumab | 17 | $165,468 |
| Enbrel SureclickEtanercept | 19 | $141,490 |
| OtezlaApremilast | 21 | $116,889 |
| EnbrelEtanercept | 12 | $87,465 |
| XeljanzTofacitinib Citrate | 12 | $68,293 |
| TymlosAbaloparatide | 13 | $32,449 |
| Hydroxychloroquine Sulfate | 514 | $16,875 |
| Celecoxib | 339 | $13,554 |
| MethotrexateMethotrexate Sodium | 498 | $13,295 |
| Duloxetine Hcl | 508 | $9,904 |
| Prednisone | 924 | $6,021 |
| Febuxostat | 52 | $5,884 |
| Pilocarpine Hcl | 49 | $5,491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla, Enbrel | $1,460 | $204,35433 claims |
| PfizerXeljanz | $734 | $68,29312 claims |
| Radius Health, Inc.Tymlos | $230 | $32,44913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 159 rheumatology providers in Virginia.
Other rheumatology in Richmond
- Michael StrachanRichmond$158K
- Karim MasriRichmond$147K
- Tammy SpringRichmond$17K
- Mihail MoroianuRichmond$13K
- Bhakti JoshiRichmond$12K
- Peter CoutlakisRichmond$12K
- Avnit AhujaRichmond$12K
- Peter LipskyCharlottesville$1.3M
- Kristi MizelleNewport News$1.1M
- Phillip KempfArlington$321K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.